MEK inhibition has been tested in pancreatic cancer as a single-agent therapy, as well as in combination with Phosphoinositide Kinase-3 (PI3K) pathway inhibition (targeting another downstream effector of KRAS9,10). Here, MAP2K7 is linked to familial pancreatic carcinoma.